News – Page 960 – Endpoints News

Gilead-partnered Vienna-based immunotherapy company Hookipa makes Nasdaq debut with downsized $84M IPO

7 years ago

France's Sanofi contributes €10M to the restoration of Notre Dame

7 years ago

Gene therapy for 'bubble boy disease' sets stage for cure

7 years ago

Serial biotech entrepreneur Michael Gilman takes his key to the $100M-plus club and goes all-in on drugging RNA

7 years ago

On a mission to make organ transplants safer and more durable, Blackstone gifts Talaris a new CEO, leads $100M round

7 years ago

GlaxoSmithKline R&D reorganization triggers layoffs at Stevenage -- and Upper Providence

7 years ago

Biotech startup grabs $27M launch round to pursue an R&D path blazed at Harvard and Boston Children’s

7 years ago

Turning Point unveils $166M IPO; Aquestive's riluzole film product is accepted for FDA review

7 years ago

In another CRISPR first, Penn researchers dose US cancer patients with gene-edited T cell therapy

7 years ago

Fresh safety, tolerability data snapshot from early-stage study of Wave's DMD drug spooks investors

7 years ago

'Patients are not a company's resource': FDA cancer czar Richard Pazdur has a bone to pick with the top R&D execs in ...

7 years ago

Ned Sharpless is not playing with the FDA’s gold standard — any more than Scott Gottlieb did

7 years ago

T cell experts at Kiadis bag CytoSen's NK cell tech, plotting a dual cancer killing approach with tips from Carl June

7 years ago

London listed PureTech Health joins forces with ninth big pharma partner — Boehringer Ingelheim

7 years ago

Revenue plunges, stock takes a drubbing, but Teva CEO Kåre Schultz still grabs $32.5M in chart-topping compensation

7 years ago

NICE backs Akcea's Tegsedi; EMA restricts Lemtrada use while it probes safety concerns

7 years ago

Chinese pharmaceutical manufacturer in spotlight after welding accident kills 10

7 years ago

Months after Regeneron secured FDA approval for 12-week Eylea regimen, Novartis buys speedy US review for its rival

7 years ago

Achaogen’s bankruptcy and going-out-of-business sale offer a grim cautionary tale for the future of antibiotic ...

7 years ago

Industry calls for changes in two REMS guidances

7 years ago

Forget biosimilars. Peter Bach and Mark Trusheim believe price controls are the better way to rein in biologics ...

7 years ago

Flagship unveils gut-focused upstart Kintai, with former GSK exec as chief

7 years ago

With $150M and a new NASH discovery deal with Gilead, AI star Daphne Koller has set out to change the drug R&D world

7 years ago

Amgen prices bone builder Evenity at $21,900/year to compete on convenience, not cost

7 years ago

First page Previous page 957 958 959960961 962 963 Next page Last page